## Aditya Raju

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8245469/publications.pdf

Version: 2024-02-01

9	222	7	9
papers	citations	h-index	g-index
9	9	9	352 citing authors
all docs	docs citations	times ranked	

#	Article	IF	Citations
1	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 8-17.e16.	0.4	74
2	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 152-160.	0.4	34
3	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 2020, 13, 421-433.	2.2	34
4	The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. Journal of Geriatric Oncology, 2018, 9, 138-144.	1.0	28
5	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 2021, 100, 2325-2337.	1.8	21
6	Treatment Patterns and Outcomes in Patients with Varicose Veins. American Health and Drug Benefits, 2016, 9, 455-465.	0.5	14
7	Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. Journal of Geriatric Oncology, 2020, 11, 41-54.	1.0	7
8	Real-World Assessment of Interventional Treatment Timing and Outcomes for Varicose Veins: A Retrospective Claims Analysis. Journal of Vascular and Interventional Radiology, 2016, 27, 58-67.	0.5	6
9	Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with TypeÂ2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis. Diabetes Therapy, 2022, 13, 25-42.	2.5	4